Vestal Point Capital’s enGene Therapeutics ENGN Stock Holding History

Vestal Point Capital’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88M	Sell	1,667,430 -497,570	-23%	-$2.03M	0.07%	64
2026 Q1	$14.7M	Buy	2,165,000 +1,110,000	+105%	+$9.88M	0.41%	59
2025 Q4	$9.53M	Buy	1,055,000 +685,000	+185%	+$5.49M	0.32%	50
2025 Q3	$2.53M	Hold	370,000	–	–	0.11%	74
2025 Q2	$1.35M	Hold	370,000	–	–	0.07%	67
2025 Q1	$1.66M	Hold	370,000	–	–	0.12%	57
2024 Q4	$2.46M	Buy	+370,000	New	+$2.87M	0.15%	65

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vestal Point Capital's ENGN Position: Q2 2026 in Review

Vestal Point Capital reduced its enGene Therapeutics (ENGN) stake by 23% in Q2 2026, selling an estimated $2.03M and leaving 1,667,430 shares worth $2.88M. The position accounts for 0.07% of the portfolio, ranked #64.

Vestal Point Capital first reported a position in ENGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.7M in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Vestal Point Capital held 1,667,430 shares of enGene Therapeutics worth $2.88M as of Q2 2026.
Vestal Point Capital sold 497,570 enGene Therapeutics shares in Q2 2026, an estimated $2.03M.
enGene Therapeutics made up 0.07% of Vestal Point Capital's portfolio in Q2 2026, its #64 holding.
Vestal Point Capital first reported a position in enGene Therapeutics in Q4 2024 and has held it in 7 quarters since.
Vestal Point Capital's enGene Therapeutics position peaked at $14.7M in Q1 2026.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.